Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara presented new exercise capacity data from the double-blind period of its IMPALA-2 Phase 3 trial for molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP). Patients treated with molgramostim showed a statistically significant greater improvement in distance walked (80.6 m difference, p=0.0301) and exercise duration (1.0 minute difference, p=0.0262) compared to placebo at Week 48.
Key figures
- Drug Name
- molgramostim inhalation solution
- Phase Of Trial
- Phase 3
- Dose mcg
- 300
- Placebo arm n
- 83
- Treatment arm n
- 81
- Distance p value
- 0.0301
- Duration p value
- 0.0262
- Treatment duration weeks
- 48
- Distance improvement placebo m
- 86.4
- Distance treatment difference m
- 80.6
- Duration improvement placebo min
- 1
- Duration treatment difference min
- 1
- Distance improvement molgramostim m
- 167
- Duration improvement molgramostim min
- 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.